Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production

Jiiang Huei Jeng, Hui Lin Wu, Bor Ru Lin, Wan Hong Lan, Hsiao Hwa Chang, Yuan Soon Ho, Po Hsuen Lee, Ying Jan Wang, Juo Song Wang, Yi Jane Chen, Mei Chi Chang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Sanguinarine is a plant alkaloid present in the root of Sanguinaria canadensis and Poppy fumaria species. Sanguinarine has been used as an antiseptic mouth rinse and a toothpaste additive to reduce dental plaque and gingival inflammation. In this study, we investigated the antiplatelet effects of sanguinarine, aiming to extend its potential pharmacological applications. Sanguinarine inhibited platelet aggregation induced by arachidonic acid (AA), collagen, U46619 and sub-threshold concentration of thrombin (0.05 U/ml) with IC50 concentrations of 8.3, 7.7, 8.6 and 4.4 μM, respectively. Sanguinarine (5-10 μM) inhibited 10-31% of platelet TXB2 production, but not platelet aggregation induced by higher concentration of thrombin (0.1 U/ml). SQ29548, a thromboxane receptor antagonist, inhibited the AA-induced platelet aggregation but not TXB2 production. Sanguinarine suppressed cyclooxygenase-1 (COX-1) activity (IC50 = 28 μM), whereas its effect on COX-2 activity was minimal. Sanguinarine (8, 10 μM) further inhibited the AA-induced Ca2+ mobilization by 27-62%. In addition, SQ22536, an adenylate cyclase inhibitor, attenuated the inhibitory effect of sanguinarine toward AA-induced platelet Ca2+ mobilization and aggregation. These results suggest that sanguinarine is a potent antiplatelet agent, which activates adenylate cyclase, inhibits platelet Ca2+ mobilization, TXB2 production as well as suppresses COX-1 enzyme activity. Sanguinarine may have therapeutic potential for treatment of cardiovascular diseases related to platelet aggregation.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalAtherosclerosis
Volume191
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Thromboxanes
Calcium
Platelet Aggregation
Arachidonic Acid
Cyclooxygenase 1
Blood Platelets
Thrombin
Inhibitory Concentration 50
Sanguinaria
Fumaria
sanguinarine
Thromboxane Receptors
Papaver
Toothpastes
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Dental Plaque
Local Anti-Infective Agents
Platelet Aggregation Inhibitors
Alkaloids
Adenylyl Cyclases

Keywords

  • Antiplatelet
  • Bleeding time
  • Calcium
  • cAMP
  • Cyclooxygenase
  • Platelet aggregation
  • Sanguinarine
  • Thromboxane

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production. / Jeng, Jiiang Huei; Wu, Hui Lin; Lin, Bor Ru; Lan, Wan Hong; Chang, Hsiao Hwa; Ho, Yuan Soon; Lee, Po Hsuen; Wang, Ying Jan; Wang, Juo Song; Chen, Yi Jane; Chang, Mei Chi.

In: Atherosclerosis, Vol. 191, No. 2, 04.2007, p. 250-258.

Research output: Contribution to journalArticle

Jeng, JH, Wu, HL, Lin, BR, Lan, WH, Chang, HH, Ho, YS, Lee, PH, Wang, YJ, Wang, JS, Chen, YJ & Chang, MC 2007, 'Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production', Atherosclerosis, vol. 191, no. 2, pp. 250-258. https://doi.org/10.1016/j.atherosclerosis.2006.05.023
Jeng, Jiiang Huei ; Wu, Hui Lin ; Lin, Bor Ru ; Lan, Wan Hong ; Chang, Hsiao Hwa ; Ho, Yuan Soon ; Lee, Po Hsuen ; Wang, Ying Jan ; Wang, Juo Song ; Chen, Yi Jane ; Chang, Mei Chi. / Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production. In: Atherosclerosis. 2007 ; Vol. 191, No. 2. pp. 250-258.
@article{5b178d12e2674879af1967504e7db81a,
title = "Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production",
abstract = "Sanguinarine is a plant alkaloid present in the root of Sanguinaria canadensis and Poppy fumaria species. Sanguinarine has been used as an antiseptic mouth rinse and a toothpaste additive to reduce dental plaque and gingival inflammation. In this study, we investigated the antiplatelet effects of sanguinarine, aiming to extend its potential pharmacological applications. Sanguinarine inhibited platelet aggregation induced by arachidonic acid (AA), collagen, U46619 and sub-threshold concentration of thrombin (0.05 U/ml) with IC50 concentrations of 8.3, 7.7, 8.6 and 4.4 μM, respectively. Sanguinarine (5-10 μM) inhibited 10-31{\%} of platelet TXB2 production, but not platelet aggregation induced by higher concentration of thrombin (0.1 U/ml). SQ29548, a thromboxane receptor antagonist, inhibited the AA-induced platelet aggregation but not TXB2 production. Sanguinarine suppressed cyclooxygenase-1 (COX-1) activity (IC50 = 28 μM), whereas its effect on COX-2 activity was minimal. Sanguinarine (8, 10 μM) further inhibited the AA-induced Ca2+ mobilization by 27-62{\%}. In addition, SQ22536, an adenylate cyclase inhibitor, attenuated the inhibitory effect of sanguinarine toward AA-induced platelet Ca2+ mobilization and aggregation. These results suggest that sanguinarine is a potent antiplatelet agent, which activates adenylate cyclase, inhibits platelet Ca2+ mobilization, TXB2 production as well as suppresses COX-1 enzyme activity. Sanguinarine may have therapeutic potential for treatment of cardiovascular diseases related to platelet aggregation.",
keywords = "Antiplatelet, Bleeding time, Calcium, cAMP, Cyclooxygenase, Platelet aggregation, Sanguinarine, Thromboxane",
author = "Jeng, {Jiiang Huei} and Wu, {Hui Lin} and Lin, {Bor Ru} and Lan, {Wan Hong} and Chang, {Hsiao Hwa} and Ho, {Yuan Soon} and Lee, {Po Hsuen} and Wang, {Ying Jan} and Wang, {Juo Song} and Chen, {Yi Jane} and Chang, {Mei Chi}",
year = "2007",
month = "4",
doi = "10.1016/j.atherosclerosis.2006.05.023",
language = "English",
volume = "191",
pages = "250--258",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production

AU - Jeng, Jiiang Huei

AU - Wu, Hui Lin

AU - Lin, Bor Ru

AU - Lan, Wan Hong

AU - Chang, Hsiao Hwa

AU - Ho, Yuan Soon

AU - Lee, Po Hsuen

AU - Wang, Ying Jan

AU - Wang, Juo Song

AU - Chen, Yi Jane

AU - Chang, Mei Chi

PY - 2007/4

Y1 - 2007/4

N2 - Sanguinarine is a plant alkaloid present in the root of Sanguinaria canadensis and Poppy fumaria species. Sanguinarine has been used as an antiseptic mouth rinse and a toothpaste additive to reduce dental plaque and gingival inflammation. In this study, we investigated the antiplatelet effects of sanguinarine, aiming to extend its potential pharmacological applications. Sanguinarine inhibited platelet aggregation induced by arachidonic acid (AA), collagen, U46619 and sub-threshold concentration of thrombin (0.05 U/ml) with IC50 concentrations of 8.3, 7.7, 8.6 and 4.4 μM, respectively. Sanguinarine (5-10 μM) inhibited 10-31% of platelet TXB2 production, but not platelet aggregation induced by higher concentration of thrombin (0.1 U/ml). SQ29548, a thromboxane receptor antagonist, inhibited the AA-induced platelet aggregation but not TXB2 production. Sanguinarine suppressed cyclooxygenase-1 (COX-1) activity (IC50 = 28 μM), whereas its effect on COX-2 activity was minimal. Sanguinarine (8, 10 μM) further inhibited the AA-induced Ca2+ mobilization by 27-62%. In addition, SQ22536, an adenylate cyclase inhibitor, attenuated the inhibitory effect of sanguinarine toward AA-induced platelet Ca2+ mobilization and aggregation. These results suggest that sanguinarine is a potent antiplatelet agent, which activates adenylate cyclase, inhibits platelet Ca2+ mobilization, TXB2 production as well as suppresses COX-1 enzyme activity. Sanguinarine may have therapeutic potential for treatment of cardiovascular diseases related to platelet aggregation.

AB - Sanguinarine is a plant alkaloid present in the root of Sanguinaria canadensis and Poppy fumaria species. Sanguinarine has been used as an antiseptic mouth rinse and a toothpaste additive to reduce dental plaque and gingival inflammation. In this study, we investigated the antiplatelet effects of sanguinarine, aiming to extend its potential pharmacological applications. Sanguinarine inhibited platelet aggregation induced by arachidonic acid (AA), collagen, U46619 and sub-threshold concentration of thrombin (0.05 U/ml) with IC50 concentrations of 8.3, 7.7, 8.6 and 4.4 μM, respectively. Sanguinarine (5-10 μM) inhibited 10-31% of platelet TXB2 production, but not platelet aggregation induced by higher concentration of thrombin (0.1 U/ml). SQ29548, a thromboxane receptor antagonist, inhibited the AA-induced platelet aggregation but not TXB2 production. Sanguinarine suppressed cyclooxygenase-1 (COX-1) activity (IC50 = 28 μM), whereas its effect on COX-2 activity was minimal. Sanguinarine (8, 10 μM) further inhibited the AA-induced Ca2+ mobilization by 27-62%. In addition, SQ22536, an adenylate cyclase inhibitor, attenuated the inhibitory effect of sanguinarine toward AA-induced platelet Ca2+ mobilization and aggregation. These results suggest that sanguinarine is a potent antiplatelet agent, which activates adenylate cyclase, inhibits platelet Ca2+ mobilization, TXB2 production as well as suppresses COX-1 enzyme activity. Sanguinarine may have therapeutic potential for treatment of cardiovascular diseases related to platelet aggregation.

KW - Antiplatelet

KW - Bleeding time

KW - Calcium

KW - cAMP

KW - Cyclooxygenase

KW - Platelet aggregation

KW - Sanguinarine

KW - Thromboxane

UR - http://www.scopus.com/inward/record.url?scp=33947198685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947198685&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2006.05.023

DO - 10.1016/j.atherosclerosis.2006.05.023

M3 - Article

VL - 191

SP - 250

EP - 258

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -